Empagliflozin: A Comprehensive Clinical and Pharmacological Profile

I. Introduction and Overview

A. Brief Introduction to Empagliflozin and its Class (SGLT2 Inhibitors)

Empagliflozin is a small molecule drug classified as a Sodium-Glucose Co-transporter 2 (SGLT2) inhibitor.[1] SGLT2 inhibitors represent a significant class of oral antidiabetic medications that exert their therapeutic effects by targeting the SGLT2 proteins predominantly located in the S1 segment of the proximal convoluted tubules of the kidneys.[1] These transporters are responsible for reabsorbing the majority (approximately 90%) of glucose filtered by the glomeruli back into the bloodstream.[1] By selectively inhibiting SGLT2, empagliflozin reduces the renal reabsorption of glucose, consequently lowering the renal threshold for glucose and promoting its excretion in the urine (glucosuria).[1] This mechanism effectively lowers elevated blood glucose levels in patients with type 2 diabetes mellitus (T2DM).

B. Historical Background and Development

The journey leading to the development of SGLT2 inhibitors like empagliflozin began with the discovery of phlorizin in 1835, a naturally occurring glucoside isolated from the bark of apple trees.[1] Phlorizin was identified as an inhibitor of SGLTs, but its clinical utility was hampered by a lack of specificity for SGLT2 over SGLT1 (another SGLT isoform primarily found in the small intestine and to a lesser extent in the S3 segment of the proximal tubule) and significant gastrointestinal side effects.[1] Initial efforts to develop more suitable SGLT inhibitors led to O-glucoside analogs of phlorizin, such as remogliflozin etabonate; however, these compounds proved to be relatively unstable from a pharmacokinetic perspective [User Query].

A pivotal advancement was the development of C-glucoside analogs. Unlike O-glucosides, C-glucosides are resistant to enzymatic cleavage by β-glucosidases in the gastrointestinal tract, leading to improved pharmacokinetic stability and oral bioavailability. Empagliflozin (development code BI 10773) is one such C-glycosyl compound.[5] This structural modification, where the glucose moiety is linked to the aglycone via a carbon-carbon bond instead of an oxygen-carbon bond, was instrumental in overcoming the limitations of earlier SGLT inhibitors. This evolution from a non-selective natural product to highly specific, stable synthetic compounds like empagliflozin exemplifies a significant achievement in medicinal chemistry, driven by a deeper understanding of molecular targets and a focused effort to enhance therapeutic profiles while minimizing off-target effects. The improved stability and selectivity offered by the C-glucoside structure were crucial for developing a clinically viable drug.

Empagliflozin received marketing authorization from the European Medicines Agency (EMA) in May 2014 [7] and from the U.S. Food and Drug Administration (FDA) in August 2014.[2] These approvals followed those of other SGLT2 inhibitors, canagliflozin (FDA approved in 2013) and dapagliflozin (EMA approved in 2012, FDA in 2014).[10] The regulatory journey for empagliflozin encountered a temporary hurdle in March 2014 when its New Drug Application (NDA) was initially rejected by the FDA due to concerns about particle contamination at a Boehringer Ingelheim manufacturing facility. These issues were subsequently addressed, leading to the drug's approval later that year.[10] While such a delay could have potentially impacted its initial market positioning relative to competitors, the robust clinical data and distinct pharmacological profile of empagliflozin, particularly its high selectivity for SGLT2, likely contributed to its subsequent successful adoption and market penetration.

C. General Summary of Therapeutic Uses

Empagliflozin was initially approved as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.[1] However, its therapeutic applications have significantly broadened over time, reflecting a growing understanding of its benefits beyond glucose lowering.

A landmark development was its approval to reduce the risk of cardiovascular (CV) death in adult patients with T2DM and established CV disease, based on the results of the EMPA-REG OUTCOME trial.[1] Subsequently, empagliflozin has been approved for the treatment of adults with symptomatic chronic heart failure, a significant advance as this indication extends to patients with both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), irrespective of their diabetes status.[3] Furthermore, it is indicated for the treatment of chronic kidney disease (CKD) in adults at risk of progression, again, regardless of diabetes status.[3] Most recently, its use has been extended to pediatric patients aged 10 years and older for glycemic control in T2DM.[3]

This expansion of indications from a purely antidiabetic agent to a therapy with proven benefits in heart failure and chronic kidney disease, even in individuals without diabetes, signifies a paradigm shift in the clinical perception and utility of empagliflozin. It underscores that its therapeutic impact is not solely dependent on glucose reduction but involves a range of pleiotropic effects on cardiovascular and renal physiology.

II. Chemical and Physical Properties

A comprehensive understanding of empagliflozin's chemical and physical properties is fundamental to appreciating its pharmacology, formulation, and therapeutic application.

A. Chemical Identification

Empagliflozin is chemically identified as:

• IUPAC Name: (2S,3R,4R,5S,6R)-2-oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol.[5] An alternative chemical name is (1S)-1,5-anhydro-1-(4-chloro-3-{4-benzyl}phenyl)-D-glucitol.[1]
• CAS Number: 864070-44-0.[1] Deprecated CAS numbers include 1240076-01-0 and 1314556-33-6.[5]
• Chemical Formula: C23​H27​ClO7​.[1]
• Molecular Weight:
• Average: 450.91 g/mol [5] or 450.912 Da.[1]
• Monoisotopic: 450.1445309 Da [1] or 450.14 g/mol.[7]
• Type: Empagliflozin is classified as a Small Molecule [1] and a synthetic organic compound.[7] Structurally, it is a C-glycosyl compound, an aromatic ether, a tetrahydrofuryl ether, and a member of monochlorobenzenes.[5] The C-glycosyl nature is particularly significant; this structural feature, where the glucosyl moiety is directly linked to the aglycone via a carbon-carbon bond, confers greater stability against enzymatic hydrolysis in the gastrointestinal tract compared to earlier O-glycoside SGLT inhibitors, which were prone to degradation.[5] This enhanced stability was a critical factor in its successful development as an orally administered drug.

B. Structure

The precise three-dimensional arrangement of atoms in empagliflozin is crucial for its selective binding to SGLT2. Standardized chemical structure representations include:

• SMILES (Simplified Molecular Input Line Entry System): C1COC[C@@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4C@@HO)Cl.[5] The canonical SMILES string further specifies the molecule's connectivity and chirality.
• InChI (International Chemical Identifier): InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1.[5]
• InChIKey: OBWASQILIWPZMG-QZMOQZSNSA-N.[5]
• Structural Description: Empagliflozin is a C-glycosyl compound where a β-D-glucopyranosyl ring is attached at its anomeric carbon to a substituted phenyl ring. Specifically, it is (1S)-1,5-anhydro-1-C-(4-chloro-3-((4-(((3S)-tetrahydrofuran-3-yl)oxy)phenyl)methyl)phenyl)-D-glucitol.[1] The presence of the chloro substituent and the tetrahydrofuran-yloxy-benzyl moiety on the aglycone part are key features contributing to its binding affinity and selectivity for SGLT2.

C. Physical Characteristics

The physical properties of empagliflozin influence its formulation, stability, and biopharmaceutical behavior:

• Appearance: It is described as a white to yellowish powder [24] or a solid.[22]
• Solubility: Empagliflozin exhibits variable solubility. It is very slightly soluble in water, slightly soluble in acetonitrile and ethanol, sparingly soluble in methanol, and practically insoluble in toluene.[24] In other solvents, it is reported as insoluble in H2O, but soluble in DMSO ($\ge$20.75 mg/mL) and ethanol ($\ge$7.06 mg/mL with sonication).[22] This solubility profile is important for its dissolution from solid dosage forms and subsequent absorption.
• Melting Point: The melting point is consistently reported in a narrow range: 152 °C [25] and 151-153°C.[26]
• Hygroscopicity and Polymorphism: Empagliflozin is not hygroscopic, and no polymorphism has been observed. It is neither a hydrate nor a solvate.[24] These characteristics are highly advantageous for pharmaceutical manufacturing, as they contribute to the stability of the drug substance and simplify formulation development, ensuring consistent product quality and performance without concerns about changes in crystal form or water uptake during storage.
• Partition Coefficient: The lipophilicity is indicated by log P = log D (pH 7.4) of 1.7.[24] The calculated XLogP3 value is 2.51.[7] These values suggest moderate lipophilicity, consistent with a drug designed for oral absorption.

D. Other Identifiers

Empagliflozin is cataloged under various identifiers across different databases and regulatory systems, reflecting its journey from a research compound (BI 10773) to a globally recognized medicine:

• DrugBank ID: DB09038.[1]
• ATC Code: A10BK03 (Empagliflozin). The full Anatomical Therapeutic Chemical (ATC) classification is: A (Alimentary tract and metabolism) > A10 (Drugs used in diabetes) > A10B (Blood glucose lowering drugs, excl. insulins) > A10BK (Sodium-glucose co-transporter 2 (SGLT2) inhibitors).[5]
• MeSH Terms: Key Medical Subject Headings include "empagliflozin," "BI 10773," "Jardiance," and its chemical name "1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene".[5]
• UNII (Unique Ingredient Identifier): HDC1R2M35U.[5]
• Synonyms: Common synonyms include Empagliflozina, Empagliflozine, Empagliflozinum, and the research code BI 10773.[1]
• WHO Essential Medicines List: Empagliflozin is included on the WHO Model List of Essential Medicines for the treatment of Type 2 diabetes mellitus, available in 10 mg and 25 mg oral solid formulations.[3] Its inclusion underscores its global health importance and favorable benefit-risk profile for a core indication.
• Lipinski's Rule of Five: Empagliflozin does not violate any of Lipinski's rules (number of violations = 0).[7] It has 6 hydrogen bond acceptors and 4 hydrogen bond donors, with 6 rotatable bonds and a topological polar surface area (TPSA) of 108.61 Ų.[7] Adherence to Lipinski's rules is generally predictive of good oral bioavailability and "drug-likeness," which are desirable characteristics for an orally administered medication intended for chronic use.

The following table summarizes key chemical and physical properties of empagliflozin:

Table 1: Chemical and Physical Properties of Empagliflozin

Property	Value	Reference(s)
IUPAC Name	(2S,3R,4R,5S,6R)-2-oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol	5
CAS Number	864070-44-0	User Query, 1
Chemical Formula	C23​H27​ClO7​	1
Average Molecular Weight	450.91 g/mol	1
Monoisotopic Mol. Weight	450.1445309 Da	1
Appearance	White to yellowish powder; Solid	22
Solubility (Water)	Very slightly soluble	24
Solubility (DMSO)	$\ge$20.75 mg/mL	22
Solubility (Ethanol)	Slightly soluble; $\ge$7.06 mg/mL (with ultrasonic)	22
Melting Point	151-153 °C	25
log P (pH 7.4)	1.7	24
XLogP3	2.51	7
WHO Essential Medicine	Yes (for Type 2 Diabetes Mellitus)	3
ATC Code	A10BK03	5
Lipinski's Rule Violations	0	7

III. Mechanism of Action and Pharmacodynamics

Empagliflozin's therapeutic effects are derived from its specific interaction with renal glucose transport mechanisms and subsequent broader physiological impacts.

A. Primary Mechanism: SGLT2 Inhibition

Empagliflozin functions as a reversible, potent, and competitive inhibitor of the Sodium-Glucose Co-transporter 2 (SGLT2).[3] SGLT2 is a high-capacity, low-affinity transporter located almost exclusively on the apical membrane of epithelial cells in the early (S1 segment) proximal convoluted tubules of the kidney's nephrons.[3] This transporter plays a crucial role in glucose homeostasis by mediating the reabsorption of approximately 90% of the glucose filtered by the glomeruli back into the systemic circulation.[1]

By inhibiting SGLT2, empagliflozin effectively blocks this reabsorptive pathway. This action reduces the amount of glucose reabsorbed from the tubular fluid and consequently lowers the renal threshold for glucose (RTG) – the plasma glucose concentration above which glucose begins to appear in the urine.[1] The net effect is a significant increase in urinary glucose excretion (UGE), which directly contributes to lowering plasma glucose levels in individuals with hyperglycemia.

A key characteristic of empagliflozin's mechanism is its independence from beta-cell function and insulin pathways.[28] Unlike many other antidiabetic agents that rely on insulin secretion or insulin sensitivity for their effects, empagliflozin's action is primarily renal. This insulin-independent mechanism confers several advantages: it allows empagliflozin to be effective across various stages of T2DM, even when beta-cell function has declined significantly, and it inherently carries a low risk of causing hypoglycemia when used as monotherapy, as it does not stimulate endogenous insulin release or directly enhance insulin action in peripheral tissues.

B. Selectivity for SGLT2 over SGLT1 and other SGLTs

A critical pharmacological feature of empagliflozin is its high selectivity for SGLT2 over SGLT1 and other SGLT isoforms (SGLT3, SGLT4, SGLT5, SGLT6). SGLT1 is primarily responsible for glucose and galactose absorption in the small intestine and reabsorbs the remaining ~10% of filtered glucose in the S3 segment of the renal proximal tubule.[29] Inhibition of intestinal SGLT1 can lead to gastrointestinal side effects such as diarrhea and malabsorption.

Empagliflozin demonstrates a selectivity for human SGLT2 that is reported to be approximately 2700-fold to over 5000-fold greater than for human SGLT1.[5] More specifically, reported IC50 values (the concentration of drug required to inhibit 50% of transporter activity) are:

• For SGLT2: 1.3 nM [24] or 3.1 nM.[6]
• For SGLT1: 6278 nM [24] or >8300 nM.[6]
• For other SGLTs (SGLT4, SGLT5, SGLT6): IC50 values are substantially higher, typically in the range of 1100–11,000 nM, indicating significantly lower potency against these transporters.[6]

This high degree of selectivity for SGLT2 is a distinguishing feature among the "flozin" class of drugs, with empagliflozin noted as having one of the highest SGLT2/SGLT1 selectivity ratios.[2] Such selectivity is clinically important as it minimizes the potential for SGLT1-mediated adverse effects, particularly in the gastrointestinal tract. The precise targeting of renal SGLT2 also contributes to a more predictable glucosuric effect.

Kinetic radioligand binding studies have confirmed the competitive nature of empagliflozin's interaction with SGLT2. The presence of high physiological glucose concentrations can lower the association rate of empagliflozin with the transporter, thereby reducing its apparent affinity, which is characteristic of competitive inhibition.[6] It is also noteworthy that selectivity profiles can vary between species; for instance, empagliflozin is less selective for SGLT2 over SGLT1 in rats compared to humans, an observation attributed to differences in critical amino acid residues within the transporter proteins across species.[6] This highlights the importance of evaluating drug candidates in human-derived systems or relevant animal models that accurately reflect human transporter pharmacology.

C. Pharmacodynamic Effects

The inhibition of SGLT2 by empagliflozin initiates a cascade of pharmacodynamic effects that extend beyond simple glucose lowering, contributing to its broad therapeutic benefits.

1. Renal Effects (Urinary Glucose Excretion, Renal Threshold for Glucose):

The primary pharmacodynamic consequence of SGLT2 inhibition is a dose-dependent increase in UGE.4 This effect is observed rapidly after administration and is sustained with chronic treatment.4 In patients with T2DM, daily UGE can increase by approximately 64 grams with a 10 mg dose and 78 grams with a 25 mg dose of empagliflozin.4 The magnitude of glucosuria is dependent on the prevailing plasma glucose concentration and the patient's glomerular filtration rate (GFR); higher plasma glucose levels and adequate GFR result in greater UGE.28 This increased UGE effectively removes excess glucose from the body. A transient increase in urinary volume, reflecting osmotic diuresis, may also occur, particularly in the initial phase of treatment 4, although some studies note no relevant impact on 24-hour urine volume with chronic use.29

2. Glycemic Control:

The enhanced UGE directly translates into improved glycemic control. Empagliflozin leads to reductions in fasting plasma glucose (FPG), post-prandial plasma glucose (PPG) levels, and smaller glucose excursions during oral glucose tolerance tests.6 Chronic administration results in clinically significant reductions in glycated hemoglobin (HbA1c) levels in patients with T2DM.6 Improvements in surrogate markers of beta-cell function, such as the Homeostasis Model Assessment-β (HOMA-β), have also been observed, potentially due to reduced glucotoxicity.24 The insulin-independent mechanism ensures efficacy even when endogenous insulin production is impaired, a common feature in advanced T2DM.

3. Cardiovascular Effects (Blood Pressure, Arterial Stiffness, Cardiac Load):

Empagliflozin exerts several favorable effects on the cardiovascular system. It consistently reduces both systolic and diastolic blood pressure.3 This antihypertensive effect is thought to be mediated, at least in part, by osmotic diuresis and natriuresis resulting from increased glucose and sodium excretion.28 By reducing sodium reabsorption in the proximal tubule, empagliflozin increases sodium delivery to the distal tubule.4 This can lead to a reduction in plasma volume, which in turn may lower both cardiac preload (the stretch on cardiac myocytes before contraction) and afterload (the resistance the heart must overcome to eject blood).4 These hemodynamic changes can alleviate cardiac workload.

Furthermore, empagliflozin has been associated with downregulation of sympathetic nervous system activity and reduced left ventricular wall stress, as evidenced by lower N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.[28] In preclinical studies (diabetic rats), empagliflozin improved endothelial dysfunction and reduced arterial stiffness.[6] Importantly, empagliflozin does not cause clinically relevant prolongation of the QTc interval, a measure of cardiac repolarization.[4]

4. Renal Protective Mechanisms (Intraglomerular Pressure, Tubuloglomerular Feedback):

The renal benefits of empagliflozin are multifaceted. Increased sodium delivery to the macula densa in the distal tubule, a consequence of proximal SGLT2 inhibition, is believed to activate tubuloglomerular feedback (TGF).4 Activation of TGF leads to afferent arteriolar vasoconstriction, which reduces intraglomerular pressure and filtration.32 This reduction in glomerular hyperfiltration is considered a key mechanism for protecting the kidneys from damage, particularly in conditions like diabetic nephropathy.

Treatment with empagliflozin is associated with an initial, modest, and often transient decrease in eGFR, which is thought to reflect these acute hemodynamic changes.[3] This initial dip is typically followed by stabilization or a slower rate of eGFR decline over the long term compared to placebo, indicating preservation of kidney function.[3] This characteristic eGFR trajectory is important for clinicians to recognize to avoid premature discontinuation of a potentially renoprotective therapy. Preclinical studies in diabetic animal models have shown that empagliflozin attenuates early signs of nephropathy.[6]

Beyond hemodynamic effects, other proposed renal protective mechanisms include optimization of renal energy metabolism (e.g., through increased ketone body utilization), regulation of autophagy, maintenance of cellular homeostasis, attenuation of sympathetic activity, and direct anti-inflammatory, anti-oxidative stress, and anti-fibrotic effects within the kidney.[32] For example, empagliflozin has been shown to suppress the advanced glycation end products (AGEs)-RAGE (receptor for AGEs) axis and downregulate the transforming growth factor-beta (TGF-β)-Smad pathway, both of which are implicated in the pathogenesis of diabetic kidney disease.[33]

5. Effects on Body Weight and Metabolic Parameters:

Empagliflozin treatment is consistently associated with a modest reduction in body weight.6 This weight loss is primarily attributed to the caloric loss resulting from urinary glucose excretion (approximately 4 kcal per gram of glucose excreted) and is predominantly due to a reduction in adipose tissue mass.6

The drug may also induce a metabolic shift towards a catabolic state, characterized by an increased glucagon-to-insulin ratio, which can promote lipolysis and hepatic ketogenesis.[31] The resulting ketone bodies can serve as an alternative and efficient energy substrate for the heart and kidneys, which may contribute to its organ-protective effects.[31]

Other metabolic changes observed include a slight increase in low-density lipoprotein cholesterol (LDL-C) levels, typically in the range of 2-4% from baseline [3], and an increase in hematocrit.[28] These parameters warrant routine monitoring.

The constellation of these pharmacodynamic effects – improved glycemic control, blood pressure reduction, weight loss, favorable hemodynamic changes, and direct renal and cardiac protective mechanisms – likely contributes synergistically to the broad spectrum of cardiorenal benefits observed with empagliflozin in major clinical trials. It is this multifaceted profile that has propelled empagliflozin beyond being solely an antidiabetic agent to a cornerstone therapy for heart failure and chronic kidney disease.

IV. Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion - ADME)

The pharmacokinetic profile of empagliflozin describes its journey through the body, encompassing absorption, distribution, metabolism, and excretion (ADME). These characteristics are crucial for determining appropriate dosing regimens and understanding its behavior in various patient populations.

A. Absorption

Empagliflozin is rapidly absorbed following oral administration.[4]

• Tmax (Time to Peak Plasma Concentration): Peak plasma concentrations (Cmax​) are typically reached at a median of approximately 1.5 hours post-dose.[4] Studies involving single and multiple oral doses ranging from 0.5 mg to 800 mg have reported Tmax​ values between 1.33 and 3.0 hours.[29] A human mass balance study using a single 50 mg oral dose observed plasma levels peaking at 1 hour post-dose.[36]
• Food Effect: The administration of a 25 mg dose of empagliflozin with a high-fat, high-calorie meal results in a slight reduction in systemic exposure. The area under the plasma concentration-time curve (AUC) decreases by approximately 16%, and Cmax​ decreases by approximately 37% compared to administration under fasted conditions.[4] However, this effect of food is not considered clinically relevant, and empagliflozin can be administered with or without food, enhancing patient convenience and adherence.[3]
• Bioavailability: While a formal absolute bioavailability study comparing intravenous to oral administration in humans was not initially submitted for EMA approval, data from a human mass-balance study suggested that at least 60% of an oral solution dose is absorbed. In this study, 54% of the administered radioactivity was recovered in urine, and about 7% was found in faeces as metabolites.[38] Animal studies indicated moderate oral bioavailability in rats (31%) and high bioavailability in mice (90-97%) and dogs (89%).[39]
• Pharmacokinetic Linearity: Empagliflozin exhibits dose-proportional pharmacokinetics over its therapeutic dose range. Increases in AUC and Cmax​ are proportional to the administered dose.[24] With once-daily dosing, steady-state plasma concentrations are achieved by the fifth dose.[24] The similarity of oral clearance values at steady state to those after a single dose further supports linear pharmacokinetics with respect to time.[29]

B. Distribution

Once absorbed, empagliflozin distributes throughout the body:

• Volume of Distribution (Vd): The apparent steady-state volume of distribution (Vdss​) is estimated to be 73.8 liters, based on population pharmacokinetic analyses.[4] This value suggests distribution into tissues beyond the plasma compartment.
• Plasma Protein Binding: Empagliflozin is moderately to highly bound to human plasma proteins, with a binding percentage of approximately 86.2%.[4] This level of protein binding can influence the free fraction of the drug available for pharmacological activity and elimination.
• Red Blood Cell (RBC) Partitioning: Following oral administration of radiolabeled empagliflozin ([14C]-empagliflozin) to healthy subjects, the drug showed moderate partitioning into red blood cells, with an RBC-to-plasma ratio of approximately 36.8%.[4] Consequently, total drug exposure is lower in whole blood compared to plasma.[36]

C. Metabolism

Empagliflozin undergoes limited metabolism in humans:

• Primary Metabolic Pathway: The primary route of metabolism for empagliflozin is glucuronidation.[4] Overall, metabolic processes play a relatively minor role in the clearance of empagliflozin.[35]
• UGT Enzymes Involved: Glucuronidation is mediated by several uridine 5'-diphospho-glucuronosyltransferase (UGT) isoforms, principally UGT2B7, UGT1A3, UGT1A8, and UGT1A9.[4] The involvement of UGT enzymes, rather than cytochrome P450 (CYP450) enzymes, as the primary metabolic pathway generally reduces the potential for many common drug-drug interactions. Studies investigating the impact of UGT2B7 genetic polymorphisms found no clinically significant effect on empagliflozin pharmacokinetics, suggesting a predictable metabolic profile across diverse populations with varying UGT2B7 genotypes.[35]
• Key Metabolites: No major active metabolites of empagliflozin have been detected in human plasma.[4] The most abundant metabolites identified are three pharmacologically inactive glucuronide conjugates: 2-O-glucuronide, 3-O-glucuronide, and 6-O-glucuronide. The systemic exposure to each of these metabolites is low, typically less than 10% of the total drug-related material in plasma.[4] In urine, two glucuronide conjugates are the most prominent metabolites, accounting for 7.8% to 13.2% of the administered dose.[35] A tetrahydrofuran ring-opened carboxylic acid metabolite is the most abundant metabolite found in faeces, representing about 1.9% of the dose.[35]
• CYP450 Involvement: In vitro studies indicate that empagliflozin does not inhibit, inactivate, or induce major CYP450 isoforms. This further minimizes the likelihood of clinically significant drug-drug interactions mediated by the CYP450 system.[28]

D. Excretion

Empagliflozin and its metabolites are eliminated from the body through both renal and faecal pathways:

• Routes of Elimination: The drug is excreted in both urine and faeces.[4]
• Mass Balance: Following a single oral dose of [14C]-empagliflozin to healthy subjects, approximately 95.6% of the total administered radioactivity was recovered. Of this, 54.4% was recovered in urine and 41.2% in faeces.[4]
• Unchanged Drug vs. Metabolites in Excreta: A significant portion of the excreted drug is in the form of unchanged empagliflozin. In faeces, the majority of the drug-related radioactivity (82.9%) corresponded to the unchanged parent drug, accounting for 34.1% of the administered dose.[4] In urine, approximately half of the drug-related radioactivity (43.5%) was excreted as unchanged parent drug, representing 23.7% of the dose.[4] This indicates that empagliflozin is eliminated primarily as the unchanged compound.[36]
• Half-life (t1/2​): The apparent terminal elimination half-life of empagliflozin is estimated to be approximately 12.4 hours based on population pharmacokinetic analysis.[4] Single rising-dose studies reported a range of 5.6 to 13.1 hours, while multiple-dose studies reported a range of 10.3 to 18.8 hours.[29] This half-life supports convenient once-daily dosing.
• Clearance (CL): The apparent oral clearance of empagliflozin is approximately 10.6 L/h, according to population pharmacokinetic analysis.[4] Oral clearance at steady state was found to be similar to that after a single dose.[29]
• Accumulation: Consistent with its half-life, once-daily dosing of empagliflozin leads to a modest accumulation, with up to 22% accumulation with respect to plasma AUC observed at steady state.[24]

The overall pharmacokinetic profile of empagliflozin—characterized by rapid absorption, suitability for administration with or without food, a half-life supporting once-daily dosing, primary metabolism via UGTs to inactive metabolites (minimizing CYP-mediated interactions), and significant excretion of unchanged drug—is generally favorable for a medication intended for chronic management of conditions like T2DM, heart failure, and CKD.

E. Pharmacokinetics in Special Populations

The pharmacokinetics of empagliflozin can be influenced by patient-specific factors such as renal and hepatic function, age, and pediatric status.

• Renal Impairment:
• Exposure to empagliflozin (AUC) increases with declining renal function. Compared to individuals with normal renal function, AUC increased by approximately 18% in mild renal impairment (eGFR 60 to <90 mL/min/1.73 m2), 20% in moderate impairment (eGFR 30 to <60 mL/min/1.73 m2), 66% in severe impairment (eGFR <30 mL/min/1.73 m2), and 48% in patients with kidney failure/end-stage renal disease (ESRD) on dialysis.[4]
• Cmax​ values were approximately 20% higher in patients with mild and severe renal impairment compared to those with normal renal function, while Cmax​ was similar in patients with moderate renal impairment and those with ESRD/on dialysis.[4]
• The apparent oral clearance of empagliflozin decreases as eGFR declines, leading to this increased drug exposure.[4]
• Crucially, the fraction of empagliflozin excreted unchanged in urine, and consequently the magnitude of urinary glucose excretion (the primary pharmacodynamic effect for glycemic control), diminishes with decreasing eGFR.[4] This dual impact—increased systemic exposure but reduced renal efficacy for glucose lowering—is a critical consideration. While early reviews suggested no clinically relevant pharmacokinetic alterations [29], more recent and detailed data from regulatory agencies confirm the increased exposure, necessitating careful dosing considerations.
• Dosage Adjustments: For glycemic control in T2DM, the FDA recommends not using empagliflozin if eGFR is less than 30 mL/min/1.73 m2.[4] The EMA suggests a 10 mg daily dose for patients with eGFR <60 mL/min/1.73 m2 and advises against initiation if eGFR is <20 mL/min/1.73 m2.[28] For its heart failure and CKD indications, empagliflozin has demonstrated benefits at lower eGFR thresholds (e.g., eGFR $\ge$20 mL/min/1.73 m2).[41]
• Hepatic Impairment:
• Systemic exposure to empagliflozin increases with the severity of hepatic impairment (Child-Pugh classification). AUC increased by approximately 23% in mild, 47% in moderate, and 75% in severe hepatic impairment compared to individuals with normal hepatic function. Corresponding increases in Cmax​ were approximately 4%, 23%, and 48%, respectively.[4]
• Dosage Adjustments: Generally, no dosage adjustment is required for patients with mild to moderate hepatic impairment.[24] However, due to limited therapeutic experience and increased exposure, the EMA does not recommend its use in patients with severe hepatic impairment.[28]
• Elderly Patients (≥75 years or ≥85 years):
• Population pharmacokinetic analyses indicate that age itself does not have a clinically meaningful impact on the pharmacokinetics of empagliflozin, and thus, no dose adjustment is typically recommended based on age alone.[24]
• However, elderly patients, particularly those aged 75 years and older, may be at an increased risk for volume depletion when taking empagliflozin. Therefore, caution and careful monitoring of volume status are advised in this population.[28] The TGA (Australia) notes limited therapeutic experience in patients aged 85 years and older and does not recommend initiation in this group.[24]
• Pediatric Patients:
• Empagliflozin has been studied in pediatric patients aged 10-17 years with T2DM in the DINAMO trial.[42] The FDA approval for this age group implies that sufficient pharmacokinetic and pharmacodynamic data were established to support its use.[4] Specific pharmacokinetic parameters for this population from the provided snippets are limited, but the approved dosing regimens are available.

The following table summarizes key pharmacokinetic parameters of empagliflozin in humans:

Table 2: Summary of Key Pharmacokinetic Parameters of Empagliflozin in Humans

Parameter	Value	Reference(s)
Tmax​ (median)	~1.5 hours	4
Effect of Food (25 mg dose)	AUC ↓ ~16%, Cmax​ ↓ ~37% (not clinically relevant)	4
Bioavailability (oral solution)	Assumed $\ge$60% (human, based on mass balance)	38
Volume of Distribution (Vdss​)	73.8 L	4
Plasma Protein Binding	86.2%	4
Primary Metabolic Pathway	Glucuronidation	4
Key Metabolizing Enzymes	UGT2B7, UGT1A3, UGT1A8, UGT1A9	4
Terminal Elimination Half-life (t1/2​)	~12.4 hours	4
Apparent Oral Clearance (CL/F)	10.6 L/h	4
% Excreted Unchanged in Urine	~23.7% of dose (43.5% of urine radioactivity)	4
% Excreted Unchanged in Faeces	~34.1% of dose (82.9% of faecal radioactivity)	4
Total Radioactivity Recovered (Urine)	54.4% of dose	4
Total Radioactivity Recovered (Faeces)	41.2% of dose	4

V. Clinical Efficacy Across Indications

Empagliflozin has demonstrated significant efficacy in large-scale clinical trials across its approved indications, establishing its role not only in glycemic management but also as a crucial agent for cardiorenal protection.

A. Type 2 Diabetes Mellitus (T2DM)

1. Glycemic Control (Monotherapy and Add-on Therapy: HbA1c, FPG, Body Weight)

Empagliflozin has consistently shown robust glycemic-lowering effects and beneficial impacts on body weight in adults with T2DM, both as monotherapy and in combination with other antidiabetic agents.

• Monotherapy: In treatment-naïve patients, empagliflozin (10 mg and 25 mg once daily) provided statistically significant and clinically meaningful reductions in HbA1c compared to placebo over 24 weeks. The placebo-adjusted mean reduction in HbA1c was approximately -0.74% for the 10 mg dose and -0.85% for the 25 mg dose [[28] (Table 2), [44]]. These improvements were accompanied by significant reductions in fasting plasma glucose (FPG) and body weight (mean placebo-adjusted weight loss of -1.93 kg to -2.15 kg) [[28] (Table 2)]. The benefits were sustained for up to 76 weeks in extension studies.[28] Patients with higher baseline HbA1c levels (e.g., $\ge$8.5%) experienced even greater HbA1c reductions.[28]
• Add-on Therapy:
• To Metformin: Empagliflozin significantly improved HbA1c, FPG, and body weight when added to metformin [[28] (Table 3), [44]]. In a 104-week head-to-head trial against glimepiride (as add-on to metformin), empagliflozin 25 mg demonstrated superior HbA1c reduction, substantial body weight loss (compared to weight gain with glimepiride), and a significantly lower incidence of hypoglycemia [[28] (Table 6), [45]].
• To Metformin plus Sulphonylurea: Empagliflozin led to significant reductions in HbA1c, FPG, and body weight compared to placebo [[28] (Table 3)].
• To Pioglitazone (with or without Metformin): Significant improvements in HbA1c and FPG were observed.[28]
• To Insulin (Basal or Multiple Daily Injections - MDI): Empagliflozin significantly decreased HbA1c, reduced the required insulin dosage (insulin-sparing effect), lowered FPG, and reduced body weight compared to placebo in studies lasting 52 to 78 weeks [[28] (Tables 7 & 8)].
• To Linagliptin plus Metformin: When added to a background of linagliptin and metformin, empagliflozin (10 mg and 25 mg) achieved significant placebo-adjusted HbA1c reductions of -0.70% to -0.79%, along with FPG and body weight reductions [[28] (Table 5)].
• Overall Glycemic Efficacy: Across various phase 3 trials, empagliflozin typically achieves HbA1c reductions ranging from -0.59% to -0.82% and body weight reductions of approximately -2.1 kg to -2.5 kg, with a low intrinsic risk of hypoglycemia when not combined with insulin or insulin secretagogues.[45]

2. Cardiovascular Outcomes (EMPA-REG OUTCOME Trial)

The EMPA-REG OUTCOME trial was a landmark study that fundamentally changed the perception of SGLT2 inhibitors, demonstrating cardiovascular benefits beyond glucose control.

• Study Design: This randomized, double-blind, placebo-controlled trial enrolled 7,028 patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD). Patients received empagliflozin (10 mg or 25 mg daily) or placebo, in addition to standard of care. The median follow-up duration was 3.1 years.[13]
• Patient Population: Participants were at high cardiovascular risk, with a mean age of 63.1 years, 72% White, 22% Asian, and 28% female. 57% had T2DM for over 10 years, and many had prior MI (47%) or multivessel disease (47%). Baseline HbA1c was approximately 8.1%, and patients were generally well-treated with other CV medications, including statins (77%).[28]
• Primary Endpoint (3-Point MACE: Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke): Empagliflozin significantly reduced the risk of 3P-MACE by 14% compared to placebo (10.5% vs. 12.1%; Hazard Ratio 0.86, 95% Confidence Interval [CI] 0.74–0.99; p=0.04 for superiority).[13]
• Key Secondary Endpoints:
• Cardiovascular (CV) Death: A striking 38% relative risk reduction was observed with empagliflozin (3.7% vs. 5.9%; HR 0.62, 95% CI 0.49–0.77; p<0.001). This was the primary driver of the 3P-MACE benefit and a pivotal finding of the trial.[13] The survival curves for CV death diverged remarkably early in the trial, suggesting rapid-acting protective mechanisms.[48]
• All-Cause Mortality: Significantly reduced by 32% (5.7% vs. 8.3%; HR 0.68, 95% CI 0.57–0.82; p<0.001).[46]
• Hospitalization for Heart Failure (HHF): Significantly reduced by 35% (2.7% vs. 4.1%; HR 0.65, 95% CI 0.50–0.85; p=0.002).[13]
• Non-fatal Myocardial Infarction (MI) and Non-fatal Stroke: No statistically significant differences were observed for these individual components (MI: 4.8% vs. 5.4%, p=0.23; Stroke: 3.5% vs. 3.0%, p=0.26).[46]
• Renal Outcomes: Empagliflozin also demonstrated significant renal benefits, reducing the risk of incident or worsening nephropathy (a composite of progression to macroalbuminuria, doubling of serum creatinine, initiation of renal-replacement therapy, or death due to renal disease) by 39% compared to placebo (12.7% vs. 18.8%; HR 0.61, 95% CI 0.53–0.70; p<0.001).[46] The consistent cardiorenal benefits observed in EMPA-REG OUTCOME, particularly the reduction in CV death, positioned empagliflozin as more than just a glucose-lowering drug, highlighting its role as a cardiorenal protective therapy. These benefits were generally consistent irrespective of baseline cardiovascular risk factor control.[13]

Table 3: Key Efficacy Endpoints from EMPA-REG OUTCOME Trial (T2DM & ASCVD)

Endpoint	Empagliflozin (N=4687) Event Rate (%)	Placebo (N=2333) Event Rate (%)	Hazard Ratio (95% CI)	p-value	Reference(s)
Primary Composite (3P-MACE)	10.5	12.1	0.86 (0.74–0.99)	0.04	46
CV Death	3.7	5.9	0.62 (0.49–0.77)	<0.001	46
All-Cause Mortality	5.7	8.3	0.68 (0.57–0.82)	<0.001	46
Hospitalization for Heart Failure	2.7	4.1	0.65 (0.50–0.85)	0.002	46
Non-fatal Myocardial Infarction	4.8	5.4	0.87 (0.70–1.09)	0.23	46 (adjusted from text)
Non-fatal Stroke	3.2	2.6	1.24 (0.92–1.67)	0.16	28 (adjusted from text)
Incident/Worsening Nephropathy	12.7	18.8	0.61 (0.53–0.70)	<0.001	46

3P-MACE: Cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

Event rates for Empagliflozin group are pooled from 10 mg and 25 mg doses.

B. Heart Failure (HF)

Empagliflozin's efficacy in heart failure has been established across the spectrum of ejection fractions, in patients with and without T2DM.

1. Heart Failure with Reduced Ejection Fraction (HFrEF) (EMPEROR-Reduced Trial)

• Study Design: This randomized, double-blind, placebo-controlled trial included 3,730 patients with chronic HFrEF (LVEF $\le$40%), NYHA class II-IV, receiving guideline-directed medical therapy (GDMT). Patients were randomized to empagliflozin 10 mg daily or placebo, with a median follow-up of 16 months.[14]
• Patient Population: Mean age was 67 years, 24% were female, and mean LVEF was 27%. Approximately 50% had T2DM. Most patients were on excellent baseline GDMT, including ACEi/ARB/ARNI (89%), beta-blockers (95%), and MRAs (71%).[14]
• Primary Endpoint (Composite of CV Death or HHF): Empagliflozin significantly reduced the risk of the primary endpoint by 25% compared to placebo (19.4% vs. 24.7%; HR 0.75, 95% CI 0.65–0.86; p<0.001).[14]
• Key Secondary Endpoints:
• Total (First and Recurrent) HHF: Significantly reduced by 30% (HR 0.70, 95% CI 0.58–0.85; p=0.0003).[14]
• Rate of eGFR Decline: Empagliflozin significantly slowed the annual rate of eGFR decline compared to placebo (–0.55 mL/min/1.73 m2/year vs. –2.28 mL/min/1.73 m2/year; difference 1.73 mL/min/1.73 m2/year, 95% CI 1.10–2.37; p<0.0001).[14]
• Composite Renal Outcome (chronic hemodialysis, renal transplantation, or profound sustained reduction in eGFR): Significantly reduced by 50% (1.6% vs. 3.1%; HR 0.50, 95% CI 0.32-0.77; p<0.01).[14]
• CV Death (individual component): Numerically lower in the empagliflozin group but not statistically significant (10.0% vs. 10.8%; HR 0.92, 95% CI 0.75-1.12).[14]
• The benefits were consistent in patients with and without T2DM.[14]

Table 4: Key Efficacy Endpoints from EMPEROR-Reduced Trial (HFrEF)

Endpoint	Empagliflozin 10 mg (N=1863) Event Rate (%)	Placebo (N=1867) Event Rate (%)	Hazard Ratio (95% CI)	p-value	Reference(s)
Primary Composite (CV Death or HHF)	19.4	24.7	0.75 (0.65–0.86)	<0.001	14
Total HHF (first and recurrent)	Event Count: 388	Event Count: 553	0.70 (0.58–0.85)	0.0003	14
Annual Rate of eGFR Decline (mL/min/1.73m²/year)	-0.55	-2.28	Difference: 1.73 (1.10–2.37)	<0.0001	14
Composite Renal Outcome	1.6	3.1	0.50 (0.32–0.77)	<0.01	14

2. Heart Failure with Preserved Ejection Fraction (HFpEF) (EMPEROR-Preserved Trial)

The EMPEROR-Preserved trial was groundbreaking as it demonstrated a clear benefit for a pharmacological agent in the historically difficult-to-treat HFpEF population.

• Study Design: This randomized, double-blind, placebo-controlled trial enrolled 5,988 patients with chronic HFpEF (LVEF >40%), NYHA class II-IV, with or without T2DM. Patients received empagliflozin 10 mg daily or placebo on top of usual therapy, with a median follow-up of 26.2 months.[15]
• Patient Population: Mean age was 71.9 years, 44.7% were women, and mean LVEF was 54.3%. Approximately 49% had T2DM. Baseline LVEF distribution: <50% (33.1%), 50% to <60% (34.4%), $\ge$60% (32.5%).[16]
• Primary Endpoint (Composite of CV Death or HHF): Empagliflozin significantly reduced the risk by 21% compared to placebo (13.8% vs. 17.1%; HR 0.79, 95% CI 0.69–0.90; p=0.0003). The benefit was observed early, reaching statistical significance at 18 days after randomization.[15] The reduction in this primary endpoint was mainly driven by a lower risk of HHF.[18]
• Key Secondary Endpoints:
• Total (First and Recurrent) HHF: Significantly reduced with empagliflozin (HR 0.73, 95% CI 0.61–0.88; p=0.0009).[16]
• Rate of eGFR Decline: Empagliflozin significantly slowed the annual rate of eGFR decline (–1.25 mL/min/1.73 m2/year vs. –2.62 mL/min/1.73 m2/year for placebo; difference 1.36 mL/min/1.73 m2/year, 95% CI 1.06–1.66; p<0.0001).[16]
• Empagliflozin also reduced the risk of severe hospitalizations (requiring intensive care, vasopressors, or positive inotropic drugs) and outpatient worsening HF events (e.g., need for urgent care visits, diuretic intensification).[16] The benefits were consistent across various subgroups, including LVEF categories, diabetes status, and age groups (even $\ge$80 years).[16] While the overall CV death rate was not significantly different, the consistent reduction in HHF across the HF spectrum (HFrEF and HFpEF) is a major therapeutic advance.

Table 5: Key Efficacy Endpoints from EMPEROR-Preserved Trial (HFpEF)

Endpoint	Empagliflozin 10 mg (N=2997) Event Rate (%)	Placebo (N=2991) Event Rate (%)	Hazard Ratio (95% CI)	p-value	Reference(s)
Primary Composite (CV Death or HHF)	13.8	17.1	0.79 (0.69–0.90)	0.0003	16
Total HHF (first and recurrent)	Event Count: 407	Event Count: 541	0.73 (0.61–0.88)	0.0009	16
Annual Rate of eGFR Decline (mL/min/1.73m²/year)	-1.25	-2.62	Difference: 1.36 (1.06–1.66)	<0.0001	16

C. Chronic Kidney Disease (CKD)

1. Renal Outcomes (EMPA-KIDNEY Trial)

The EMPA-KIDNEY trial further solidified empagliflozin's role as a renoprotective agent in a broad population of patients with CKD.

• Study Design: This randomized, double-blind, placebo-controlled trial involved 6,609 adult patients with CKD (eGFR $\ge$20 to <45 mL/min/1.73 m2, or eGFR $\ge$45 to <90 mL/min/1.73 m2 with urine albumin-to-creatinine ratio $\ge$200 mg/g), with or without T2DM. Patients received empagliflozin 10 mg daily or placebo, added to standard care, and were followed for a median of 2.0 years. The trial was stopped prematurely due to demonstrated efficacy.[19]
• Patient Population: Mean age was 63.3 years, with a diverse representation of CKD causes (diabetic kidney disease 31%, glomerular disease 25%, hypertensive/renovascular disease 22%). Approximately 46% had T2DM. The mean baseline eGFR was 37.3 mL/min/1.73 m2, and patients were included across a wide range of albuminuria levels.[20]
• Primary Endpoint (Composite of Kidney Disease Progression or CV Death): Empagliflozin significantly reduced the risk of the primary composite endpoint by 28% compared to placebo (13.1% vs. 16.9%; HR 0.72, 95% CI 0.64–0.82; p<0.0001). Kidney disease progression was defined as a sustained $\ge$40% decline in eGFR from randomization, sustained eGFR <10 mL/min/1.73 m2, end-stage kidney disease (ESKD - initiation of maintenance dialysis or kidney transplant), or renal death.[19]
• Key Secondary Endpoints:
• All-Cause Hospitalization (first and recurrent): Significantly reduced by 14% (HR 0.86, 95% CI 0.78–0.95; p=0.0025).[19]
• Rate of eGFR Decline: The annual rate of eGFR decline was significantly slower in the empagliflozin group compared to placebo (difference of 1.37 mL/min/1.73 m2/year, 95% CI 1.16–1.59).[28] Other sources report a 50% reduction in the rate of eGFR decline per year.[53]
• Endpoints such as HHF or CV death (as a composite) or all-cause death were not statistically significant individually, which may be attributable to the lower number of events observed due to the trial's early termination.[53]
• The benefits were generally consistent across various prespecified subgroups, including patients with or without diabetes, different eGFR categories, and different underlying causes of CKD.[20]

Table 6: Key Efficacy Endpoints from EMPA-KIDNEY Trial (CKD)

Endpoint	Empagliflozin 10 mg (N=3304) Event Rate (%)	Placebo (N=3305) Event Rate (%)	Hazard Ratio (95% CI or 99.83% CI for Primary)	p-value	Reference(s)
Primary Composite (Kidney Disease Progression or CV Death)	13.1	16.9	0.72 (0.64–0.82) or (0.59-0.89 for 99.83% CI)	<0.0001	19
All-Cause Hospitalization (first and recurrent)	Event Count: 1611	Event Count: 1895	0.86 (0.78–0.95) or (0.75-0.98 for 99.03% CI)	0.0025	19
Annual Rate of eGFR Decline (mL/min/1.73m²/year vs Placebo)	Slower by 1.37		(95% CI 1.16–1.59)	<0.0001	28

D. Pediatric Type 2 Diabetes Mellitus

1. Glycemic Control and Safety (DINAMO Trial)

The DINAMO (DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents) trial evaluated empagliflozin in a younger population with T2DM, an area with limited oral treatment options.

• Study Design: This multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 trial enrolled 158 participants aged 10–17 years with T2DM (HbA1c 6.5%–10.5%) who were inadequately controlled with diet and exercise, with or without metformin and/or insulin. Patients received empagliflozin (10 mg or 25 mg pooled for analysis), linagliptin 5 mg, or placebo once daily for 26 weeks, followed by a safety extension period up to 52 weeks.[21]
• Patient Population: Mean age ~14-15 years. At baseline, 51% were on metformin alone, 40% on metformin plus insulin, and 3% on insulin alone.[21]
• Primary Endpoint (Change from Baseline in HbA1c at Week 26):
• Empagliflozin vs. Placebo: Empagliflozin demonstrated a statistically significant reduction in HbA1c. The adjusted mean difference in HbA1c change from baseline was -0.84% (95% CI -1.50 to -0.19; p=0.012) in favor of empagliflozin.[21] Specifically, patients on empagliflozin had a mean HbA1c decrease of 0.2% from baseline, while those on placebo had a mean increase of 0.7%.[21]
• Linagliptin vs. Placebo: Linagliptin did not show a statistically significant reduction in HbA1c compared to placebo (adjusted mean difference -0.34%, 95% CI -0.99 to 0.30; p=0.29).[43]
• Secondary Endpoints:
• Fasting Plasma Glucose (FPG): Empagliflozin treatment resulted in a significant reduction in FPG compared to placebo (adjusted mean difference -35.18 mg/dL, 95% CI -58.61 to -11.74).[21]
• Safety: The safety profile of empagliflozin in pediatric patients was generally similar to that observed in adults. However, a higher risk of hypoglycemia was reported in pediatric patients treated with empagliflozin compared to placebo, regardless of concomitant insulin use.[4] No cases of diabetic ketoacidosis or necrotizing fasciitis were noted in the empagliflozin arm of the DINAMO trial.[43] This higher hypoglycemia risk in the pediatric population, even without concomitant insulin secretagogues, is a key distinction from the adult safety profile and necessitates careful monitoring and patient education.

Table 7: Key Efficacy Endpoints from DINAMO Trial (Pediatric T2DM at Week 26)

Endpoint	Empagliflozin (pooled) vs. Placebo	95% CI	p-value	Reference(s)
Adjusted Mean Change in HbA1c from Baseline	-0.84%	(-1.50 to -0.19)	0.012	21
Adjusted Mean Change in FPG from Baseline (mg/dL)	-35.18	(-58.61 to -11.74)	N/A	43

FPG data comparison vs placebo, adjusted mean (95% CI).

E. Efficacy in Specific Patient Subgroups

The benefits of empagliflozin have been largely consistent across various patient subgroups in the major clinical trials:

• Elderly Patients: In the EMPEROR-Preserved trial (HFpEF), empagliflozin demonstrated similar efficacy in reducing the primary outcome and improving quality of life (KCCQ scores) across all age groups, including those $\ge$80 years, without significant differences in adverse events.[52] However, it is important to note that elderly patients may have a higher baseline risk of volume depletion and reduced renal function, requiring careful monitoring.[28]
• Renal Impairment:
• In EMPA-REG OUTCOME (T2DM with ASCVD), the cardiovascular and renal benefits of empagliflozin were consistent in patients with pre-existing CKD (e.g., eGFR <60 mL/min/1.73 m2 or macroalbuminuria).[46]
• In the EMPEROR heart failure trials (Reduced and Preserved), benefits on primary endpoints and eGFR slope were consistent down to an eGFR of 20 mL/min/1.73 m2.[14]
• The EMPA-KIDNEY trial specifically demonstrated benefits in a broad CKD population, including those with eGFR as low as 20 mL/min/1.73 m2 and across various levels of albuminuria.[20]
• LVEF Categories in HFpEF: In EMPEROR-Preserved, the reduction in the primary composite endpoint (CV death or HHF) was generally consistent across LVEF subgroups (LVEF >40% to <50%, 50% to <60%, and $\ge$60%).[16] One analysis suggested a possible attenuation of benefit on total HHF at very high LVEFs (e.g., >65%), though this did not appear to correlate with age.[16]
• Diabetes Status: In the dedicated heart failure (EMPEROR-Reduced, EMPEROR-Preserved) and CKD (EMPA-KIDNEY) trials, the observed benefits of empagliflozin on primary and key secondary endpoints were largely consistent in patients with and without T2DM.[14] This consistency strongly supports the understanding that empagliflozin's protective mechanisms in HF and CKD extend beyond its glucose-lowering effects.

VI. Safety Profile

A thorough understanding of empagliflozin's safety profile, including adverse drug reactions (ADRs), contraindications, warnings, and precautions, is essential for its appropriate and safe clinical use.

A. Overview of Adverse Drug Reactions (ADRs)

The safety profile of empagliflozin has been evaluated extensively in clinical trials across its various indications.

• Common ADRs (reported with an incidence of $\ge$5% in some studies or frequently noted):
• Genitourinary Infections:
• Genital Mycotic Infections (GMIs): These are among the most frequently reported ADRs, including vaginal moniliasis, vulvovaginitis in females, and balanitis or other penile infections in males.[3] In T2DM trials, the incidence for empagliflozin 10 mg and 25 mg was around 4%, compared to 1% for placebo, with higher rates in females.[28] These are attributed to increased glucosuria creating a favorable environment for fungal growth.[58] Most infections are mild to moderate in intensity.[28]
• Urinary Tract Infections (UTIs): Also common, with reported incidences in T2DM trials for empagliflozin 10 mg around 8.8%, and for 25 mg around 7.0%, compared to 7.2% for placebo.[3] While some reviews suggest no significant overall increase in risk compared to placebo or other antidiabetics [3], a meta-analysis indicated an increased risk of UTIs specifically with empagliflozin compared to dapagliflozin and canagliflozin.[61] UTIs can occasionally be serious, leading to complications like pyelonephritis or urosepsis.[4]
• Hypoglycemia: The risk is very common when empagliflozin is used concomitantly with insulin or insulin secretagogues (e.g., sulphonylureas).[4] When used as monotherapy or with agents not typically causing hypoglycemia (like metformin), the intrinsic risk is low due to its insulin-independent mechanism. In pediatric patients, a higher risk of hypoglycemia was observed regardless of insulin use.[4]
• Volume Depletion-Related Events: Events such as hypotension, dizziness, or syncope can occur, particularly in at-risk populations (elderly, renal impairment, patients on diuretics).[3] In the EMPEROR heart failure studies, volume depletion was reported in 11.4% of empagliflozin-treated patients versus 9.7% in the placebo group.[28]
• Increased Urination (Pollakiuria): Reported more frequently with empagliflozin (around 3.3-3.5%) compared to placebo (1.4%) in T2DM trials, mostly mild to moderate.[28]
• Thirst: A common symptom, likely related to osmotic diuresis.[28]
• Dyslipidemia: Slight increases in low-density lipoprotein cholesterol (LDL-C) have been observed (typically 2-4% from baseline).[3] Increases in total cholesterol and HDL-cholesterol, and slight increases in triglycerides have also been noted.[28]
• Increased Hematocrit: Modest increases in hematocrit are commonly observed.[28]
• Other common ADRs: Constipation, generalized pruritus, and rash have also been reported.[28]
• Serious ADRs (less common but clinically significant):
• Ketoacidosis (including Euglycemic Diabetic Ketoacidosis - EDKA): A rare but serious and potentially life-threatening adverse reaction. It can occur in patients with T1DM (where empagliflozin is not approved) and T2DM.[1] A particularly concerning aspect is euglycemic DKA, where ketoacidosis develops with blood glucose levels below 250 mg/dL (<14 mmol/L), potentially delaying diagnosis.[1]
• Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): A rare, but very serious and potentially fatal, rapidly progressive infection of the genital or perineal area.[4] Requires urgent surgical debridement and antibiotic treatment.
• Urosepsis and Pyelonephritis: Serious urinary tract infections that can arise from less severe UTIs if not treated promptly.[4]
• Acute Kidney Injury (AKI) and Impairment in Renal Function: While empagliflozin has long-term renal benefits, AKI has been reported, particularly in patients with risk factors such as volume depletion or concomitant nephrotoxic drugs.[3] An initial transient decrease in eGFR is often observed.
• Lower Limb Amputations: An increased risk of lower limb amputations (primarily toe) has been observed in long-term clinical studies with another SGLT2 inhibitor (canagliflozin), raising concerns about a potential class effect.[28] While the EMPA-REG OUTCOME trial did not show a significantly increased risk for empagliflozin in patients with PAD [46], regulatory labels include warnings regarding this risk.[4]
• Hypersensitivity Reactions: Serious reactions such as angioedema and urticaria have occurred.[4]
• Tubulointerstitial Nephritis: Reported very rarely.[28]

The balance between the benefits of empagliflozin, particularly its cardiorenal protective effects, and the risks of adverse events like genitourinary infections requires careful patient selection and ongoing monitoring. For GMIs and UTIs, while common, they are generally manageable. However, the potential for progression to more serious conditions like Fournier's gangrene or urosepsis necessitates prompt medical attention if symptoms arise.

B. Detailed Discussion of Key Safety Concerns

1. Ketoacidosis (including Euglycemic Diabetic Ketoacidosis - EDKA):

Diabetic ketoacidosis is a significant safety concern associated with SGLT2 inhibitors, including empagliflozin. This condition can be life-threatening and requires prompt medical intervention.4 A particularly challenging aspect is the occurrence of euglycemic DKA, where patients present with ketoacidosis but have blood glucose levels that are normal or only mildly elevated (e.g., <250 mg/dL or <14 mmol/L).1 This atypical presentation can delay diagnosis and treatment.

• Risk Factors: Several factors can increase the risk of DKA in patients taking empagliflozin. These include conditions that lead to insulin deficiency or reduced insulin requirements (e.g., pancreatic disorders like pancreatitis history or surgery, low beta-cell function reserve as in LADA), states of prolonged fasting or reduced caloric intake (e.g., due to acute illness or major surgical procedures), dehydration, alcohol abuse, and adherence to very low carbohydrate or ketogenic diets.[28]
• Incidence: DKA is considered a rare adverse event. Data from a post-marketing surveillance study in Japan reported no cases of DKA among 7,931 patients [68], while another interim analysis from the same PMS reported 0% in 7,618 patients.[69] Real-world data from New Zealand indicated an incidence of 0.23%, or 2.3 cases per 1,000 patient-years, with higher rates in younger individuals (<30 years).[64] International trial data suggests an incidence between 0.6% and 2.2% (0.6–2.2 per 1,000 patient-years) in T2DM.[64]
• Management and Prevention: Patients should be educated about the signs and symptoms of DKA (e.g., nausea, vomiting, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue, fruity-smelling breath) and advised to seek immediate medical attention if they occur, irrespective of blood glucose levels.[4] If DKA is suspected or confirmed, empagliflozin should be discontinued immediately, and appropriate DKA management protocols initiated.[4] It is recommended to temporarily interrupt empagliflozin treatment in patients hospitalized for major surgical procedures or acute serious medical illnesses, during which ketone levels should be monitored (blood ketones preferred over urine).[4] Treatment should only be restarted when ketone values are normal and the patient's condition has stabilized. Restarting empagliflozin in patients who previously developed DKA while on an SGLT2 inhibitor is generally not recommended unless another clear precipitating factor for the DKA episode was identified and has been resolved.[28] The proactive management of risk factors, such as patient education and temporary discontinuation during periods of physiological stress, is crucial for minimizing DKA risk.

2. Genitourinary Infections (Urinary Tract Infections, Genital Mycotic Infections):

Increased glucosuria due to SGLT2 inhibition creates a nutrient-rich environment in the urinary tract and genital area, predisposing patients to infections.58

• Genital Mycotic Infections (GMIs): These are common, particularly in women (vulvovaginal candidiasis) but also occur in men (balanitis, balanoposthitis).[3] Symptoms include itching, soreness, rash, and discharge. Most GMIs are mild to moderate in intensity and can often be managed with standard antifungal treatments.[28] Patients should be advised on proper genital hygiene.
• Urinary Tract Infections (UTIs): The incidence of UTIs is also increased.[3] While many UTIs are uncomplicated, there is a risk of progression to more serious conditions like pyelonephritis (kidney infection) and urosepsis, which can be life-threatening.[4] Patients should be monitored for signs and symptoms of UTIs (e.g., dysuria, urinary frequency, cloudy urine, flank pain, fever) and treated promptly if an infection occurs. Temporary interruption of empagliflozin treatment should be considered for patients with complicated UTIs.[4] A meta-analysis suggested that while the overall risk of UTIs with SGLT2 inhibitors as a class might not be significantly elevated compared to controls, empagliflozin specifically might be associated with an increased risk compared to some other SGLT2 inhibitors like dapagliflozin and canagliflozin.[61]

3. Hypotension/Volume Depletion:

Empagliflozin causes osmotic diuresis due to increased UGE, which can lead to intravascular volume contraction and symptomatic hypotension.3

• At-Risk Patients: The risk is higher in elderly patients (especially $\ge$75 years), patients with pre-existing renal impairment (eGFR <60 mL/min/1.73 m2), patients with low systolic blood pressure, and those concomitantly treated with diuretics (particularly loop diuretics).[3]
• Management: Volume status should be assessed before initiating empagliflozin, especially in at-risk patients. If volume depletion is present, it should be corrected prior to starting therapy. Patients should be monitored for signs and symptoms of hypotension (e.g., dizziness, lightheadedness, syncope). In case of conditions that may lead to fluid loss (e.g., gastrointestinal illness), careful monitoring of volume status (physical examination, blood pressure, hematocrit) and electrolytes is recommended, and temporary interruption of empagliflozin may be necessary.[4]

4. Acute Kidney Injury (AKI):

While empagliflozin demonstrates long-term renoprotective effects, cases of AKI have been reported with SGLT2 inhibitors.3

• Risk Factors: AKI is more likely in the context of volume depletion, hypotension, or concomitant use of other nephrotoxic drugs (e.g., NSAIDs, ACE inhibitors, ARBs in certain settings).
• Monitoring: Renal function should be assessed prior to initiation and periodically during treatment. If AKI occurs, empagliflozin should be discontinued promptly, and supportive treatment instituted.

5. Lower Limb Amputations:

An increased risk of lower limb amputations, primarily affecting the toes, was observed in clinical trials with canagliflozin, another SGLT2 inhibitor. This has raised concerns about a potential class effect.28

• Empagliflozin Data: The EMPA-REG OUTCOME trial did not show a statistically significant increase in lower limb amputations with empagliflozin compared to placebo, even in patients with established peripheral artery disease (PAD).[46] However, regulatory agencies (FDA and EMA) include warnings about this potential risk in the product information for empagliflozin.[4]
• Management: Patients, particularly those with diabetes and risk factors for amputation (e.g., PAD, neuropathy, history of foot ulcers), should be counseled on routine preventative foot care. Any signs of foot infections, ulcers, or new pain/tenderness in the lower limbs should be promptly evaluated.[4]

6. Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene):

This is a rare but extremely serious and potentially life-threatening bacterial infection of the soft tissues in the genital and perineal area.4

• Association with SGLT2 Inhibitors: Cases have been reported in both male and female patients taking SGLT2 inhibitors, including empagliflozin. The exact mechanism is not fully understood but may be related to the glucosuric environment favoring bacterial growth, potentially from an initial uro-genital infection or perineal abscess.[28]
• Recognition and Management: Patients should be advised to seek immediate medical attention if they experience a combination of pain, tenderness, erythema (redness), or swelling in the genital or perineal area, accompanied by fever or malaise.[4] If Fournier’s gangrene is suspected, empagliflozin must be discontinued immediately, and prompt treatment, including broad-spectrum antibiotics and urgent surgical debridement, should be instituted.[4] Early recognition and aggressive management are critical to improve outcomes. The importance of patient education on this rare but severe ADR cannot be overstated.

7. Hypoglycemia:

Empagliflozin, due to its insulin-independent mechanism, has a low intrinsic risk of causing hypoglycemia when used as monotherapy or with drugs that do not independently cause hypoglycemia (e.g., metformin).4

• Increased Risk with Concomitant Therapy: The risk of hypoglycemia is significantly increased when empagliflozin is co-administered with insulin or insulin secretagogues (e.g., sulphonylureas).[4]
• Pediatric Patients: In pediatric patients aged 10 years and older, an increased risk of hypoglycemia was observed with empagliflozin compared to placebo, irrespective of concomitant insulin use.[4]
• Management: When initiating empagliflozin in patients already on insulin or an insulin secretagogue, a reduction in the dose of these concomitant medications should be considered to mitigate the risk of hypoglycemia.[4] Patients should be educated on recognizing and managing hypoglycemia.

8. Other Adverse Drug Reactions:

• Increased LDL-C: Modest increases in LDL-cholesterol (2-4% from baseline) have been observed and should be monitored as appropriate.[3]
• Hypersensitivity Reactions: Serious hypersensitivity reactions, including angioedema and urticaria, have occurred. If such reactions occur, empagliflozin should be discontinued, and appropriate treatment initiated.[4]

C. Contraindications

Empagliflozin is contraindicated in patients with:

• A history of serious hypersensitivity reaction to empagliflozin or any of its excipients (e.g., angioedema).[4]
• For the indication of glycemic control in T2DM, it is often contraindicated or not recommended in patients with severe renal impairment (e.g., eGFR <30 mL/min/1.73 m2), end-stage renal disease (ESRD), or those on dialysis, due to diminished efficacy and potential risks.[4] However, for HF and CKD indications, its use may be permitted at lower eGFRs based on specific trial data and regulatory approvals.
• Empagliflozin should not be used in patients with type 1 diabetes mellitus (T1DM) due to an increased risk of DKA.[4]
• It is also contraindicated for the treatment of diabetic ketoacidosis.[34]

D. Warnings and Precautions (Summary from FDA/EMA Labels)

Key warnings and precautions associated with empagliflozin use include:

• Renal Function Assessment: Assess renal function before initiating therapy and periodically thereafter.[4]
• Volume Status: Assess and correct volume depletion before initiation, especially in at-risk patients.[4]
• Ketoacidosis: Monitor for signs and symptoms; educate patients. Discontinue if DKA occurs. Temporarily withhold before surgery or acute illness.[4]
• Urosepsis and Pyelonephritis: Evaluate for signs of UTIs and treat promptly.[4]
• Hypoglycemia: Increased risk with insulin/insulin secretagogues. Consider dose reduction of these agents. Higher risk in pediatric patients.[4]
• Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): Educate patients on symptoms; seek immediate medical attention if suspected. Discontinue empagliflozin.[4]
• Genital Mycotic Infections: Monitor and treat as appropriate.[4]
• Lower Limb Amputation: Monitor for infections or ulcers of lower limbs; counsel on preventative foot care.[4]
• Hypersensitivity Reactions: Discontinue if reactions like angioedema occur.[4]
• Hepatic Injury (EMA): Cases reported; causal relationship not established. Monitor if symptoms occur.[28]
• Hematocrit Elevation (EMA): Monitor in patients with pronounced elevations.[28]
• Use in Elderly: Increased risk of volume depletion; monitor closely.[4]
• Limitations of Use for CKD (FDA): Not recommended for CKD in patients with polycystic kidney disease or those requiring/recently on IV immunosuppressive therapy or high-dose prednisone for kidney disease.[4]

E. Monitoring Recommendations

Routine monitoring is essential to ensure the safe and effective use of empagliflozin:

• Renal Function (eGFR, serum creatinine): Assess prior to initiation and periodically during treatment (e.g., at least yearly, more frequently in at-risk patients or if eGFR is declining).[4]
• Volume Status and Blood Pressure: Assess prior to initiation and monitor routinely, especially in at-risk patients.[4]
• Signs and Symptoms of Infections: Educate patients to report symptoms of UTIs, GMIs, and Fournier's gangrene.[4]
• Signs and Symptoms of Ketoacidosis: Educate patients, especially those with risk factors.[4]
• Foot Care: Counsel diabetic patients on routine preventative foot care, especially those with PAD or neuropathy.[4]
• Hypoglycemia: Monitor blood glucose, especially when used with insulin/insulin secretagogues or in pediatric patients.[4]
• Lipid Profile and Hematocrit: Monitor as clinically appropriate.[28]

F. Use in Specific Populations (Safety Aspects)

• Pregnancy: Empagliflozin is not recommended during the second and third trimesters of pregnancy due to potential fetal renal adverse effects observed in animal studies. Limited data in pregnant women are available. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus, particularly during the first trimester.[11]
• Lactation: It is not known whether empagliflozin is excreted in human milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with empagliflozin.[34]
• Geriatric Use: Patients aged 75 years and older may have an increased risk of volume depletion and associated adverse reactions (e.g., hypotension, renal function decline).[4] Assess renal function and volume status more frequently.
• Renal Impairment: Increased incidence of adverse reactions related to reduced renal function and volume depletion.[4] Efficacy for glycemic control is reduced with lower eGFR.[4]
• Hepatic Impairment: While dose adjustment is typically not needed for mild to moderate impairment, empagliflozin exposure is increased. Therapeutic experience in severe hepatic impairment is limited, and use is not recommended by EMA in this population.[28]

VII. Drug Interactions

Empagliflozin has the potential for both pharmacodynamic and pharmacokinetic drug interactions that clinicians should consider. The primary metabolism of empagliflozin via UGT enzymes, rather than CYP450 enzymes, generally results in a lower potential for many common pharmacokinetic drug-drug interactions.[28] However, pharmacodynamic interactions, particularly those affecting volume status and glucose control, are clinically more significant.

A. Pharmacodynamic Interactions

These interactions arise from the combined effects of empagliflozin and other drugs on physiological parameters.

• 1. Diuretics:
• Clinical Impact: Co-administration of empagliflozin with thiazide or loop diuretics can enhance the diuretic effect of both agents. This leads to increased urine volume and frequency of urination, which may potentiate the risk of volume depletion and symptomatic hypotension.[4]
• Management: Before initiating empagliflozin, particularly in patients already on diuretics, it is crucial to assess their volume status and renal function. If volume depletion is evident, it should be corrected. During concomitant therapy, patients should be monitored for signs and symptoms of volume depletion (e.g., dizziness, orthostatic hypotension) and changes in renal function. Careful consideration of diuretic dosage may be necessary.
• 2. Insulin and Insulin Secretagogues (e.g., Sulphonylureas):
• Clinical Impact: The risk of hypoglycemia is significantly increased when empagliflozin is used in combination with insulin or insulin secretagogues.[4] Empagliflozin lowers blood glucose independently of insulin, and the additive glucose-lowering effects can lead to hypoglycemia if the doses of insulin or secretagogues are not adjusted.
• Management: When initiating empagliflozin in patients receiving these agents, a reduction in the dosage of the insulin or insulin secretagogue should be strongly considered to minimize the risk of hypoglycemia. Patients should be educated about the signs and symptoms of hypoglycemia and how to manage it. This is particularly important for pediatric patients, where an increased risk of hypoglycemia with empagliflozin has been noted regardless of insulin use.[4]
• 3. Lithium:
• Clinical Impact: SGLT2 inhibitors, including empagliflozin, can increase the renal excretion of lithium by affecting sodium and lithium reabsorption in the proximal tubules. This can lead to decreased serum lithium concentrations and potentially reduce the efficacy of lithium therapy.[4]
• Management: Serum lithium concentrations should be monitored more frequently when empagliflozin is initiated, when its dosage is changed, or if it is discontinued in patients receiving lithium. Consultation with the lithium-prescribing physician is advisable for appropriate monitoring and potential dose adjustments of lithium.

B. Pharmacokinetic Interactions

These interactions involve effects on the absorption, distribution, metabolism, or excretion of empagliflozin or co-administered drugs.

• 1. UGT Enzyme Inducers:
• Clinical Impact: Empagliflozin is primarily metabolized by UGT enzymes (UGT1A3, UGT1A8, UGT1A9, and UGT2B7).[4] Co-administration with potent inducers of UGT enzymes (e.g., rifampicin, phenytoin, phenobarbital, carbamazepine) may theoretically increase the metabolism of empagliflozin, leading to decreased plasma concentrations and potentially reduced efficacy.[28] The effect of UGT induction on empagliflozin exposure has not been definitively evaluated in vivo according to some labels.[4]
• Management: Co-treatment with known UGT inducers is generally not recommended or should be approached with caution.[28] If concomitant use is necessary, monitoring of glycemic control to assess the response to empagliflozin is appropriate. Dosage adjustments of empagliflozin might be considered, although specific guidance is limited.
• 2. UGT Enzyme Inhibitors:
• Clinical Impact: Co-administration of empagliflozin with probenecid, an inhibitor of UGT enzymes and the organic anion transporter 3 (OAT3), resulted in a 26% increase in empagliflozin Cmax​ and a 53% increase in AUC. However, these changes were not considered clinically meaningful by the EMA.[28]
• Management: No specific dose adjustments are typically required when empagliflozin is co-administered with UGT inhibitors based on current data.
• 3. Other Transporter Interactions:
• OATP1B1/1B3 Transporters: Inhibition of OATP1B1/1B3 transporters by co-administration with rifampicin (which is also a UGT inducer) led to a 75% increase in Cmax​ and a 35% increase in AUC of empagliflozin. These changes were not deemed clinically meaningful in isolation of UGT induction effects.[28]
• P-glycoprotein (P-gp): Empagliflozin is a substrate of P-gp. However, it does not inhibit P-gp at therapeutic doses. Co-administration with digoxin (a P-gp substrate) resulted in minor, not clinically meaningful, increases in digoxin exposure.[28]
• 4. Interactions with Metformin (in combination products like Synjardy/Synjardy XR):
• Metformin itself has potential interactions. Drugs that reduce metformin clearance (e.g., ranolazine, vandetanib, dolutegravir, cimetidine) can increase metformin accumulation and the risk of lactic acidosis.[73] Carbonic anhydrase inhibitors (e.g., topiramate) may also increase the risk of lactic acidosis when used with metformin.[73] Excessive alcohol intake can potentiate metformin's effect on lactate metabolism and should be avoided.[70] These interactions are relevant when empagliflozin is used in fixed-dose combinations with metformin.

C. Interference with Laboratory Tests

• Positive Urine Glucose Test: Due to its mechanism of action, empagliflozin increases urinary glucose excretion. This will invariably lead to a positive urine glucose test in patients taking the medication.[4]
• Management: Monitoring glycemic control using urine glucose tests is not recommended for patients on empagliflozin. Alternative methods, such as blood glucose monitoring and HbA1c, should be used.
• Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Measurements of 1,5-AG, a marker used by some to assess short-term glycemic control, are unreliable in patients taking SGLT2 inhibitors, including empagliflozin.[4]
• Management: The 1,5-AG assay should not be used for monitoring glycemic control in patients treated with empagliflozin.

VIII. Regulatory and Commercial Information

Empagliflozin has achieved widespread regulatory approval globally and is marketed under various brand names, primarily by the Boehringer Ingelheim and Eli Lilly and Company alliance.

A. Regulatory Approval History

• 1. FDA (USA):
• Initial approval for empagliflozin (Jardiance) was granted in August 2014 as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.[2]
• Subsequent FDA approvals expanded its indications to:
• Reduce the risk of cardiovascular death in adults with T2DM and established cardiovascular disease (December 2016, based on EMPA-REG OUTCOME).[74]
• Reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.[5615] The current label includes adults with heart failure broadly.[4]
• Reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.[4]
• Improve glycemic control in pediatric patients aged 10 years and older with T2DM (June 2023).[3]
• The FDA initially required several postmarketing studies, including a cardiovascular outcomes trial (which became EMPA-REG OUTCOME), pediatric studies, and an animal toxicity study.[3]
• 2. EMA (Europe):
• Marketing authorization for Jardiance was granted by the European Commission in May 2014 for the treatment of T2DM in adults.[3]
• Indications have since been expanded to

Works cited

1. Empagliflozin: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed May 27, 2025, https://go.drugbank.com/drugs/DB09038
2. SGLT2 inhibitor - Wikipedia, accessed May 27, 2025, https://en.wikipedia.org/wiki/SGLT2_inhibitor
3. Empagliflozin - Wikipedia, accessed May 27, 2025, https://en.wikipedia.org/wiki/Empagliflozin
4. www.accessdata.fda.gov, accessed May 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf
5. Empagliflozin | C23H27ClO7 | CID 11949646 - PubChem, accessed May 27, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Empagliflozin
6. A comprehensive review of the pharmacodynamics of the SGLT2 ..., accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5896322/
7. empagliflozin | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed May 27, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4754
8. Type 2 diabetes: European Commission approves Jardiance® (empagliflozin) tablets for use in adults in Europe | Eli Lilly and Company, accessed May 27, 2025, https://investor.lilly.com/news-releases/news-release-details/type-2-diabetes-european-commission-approves-jardiancer
9. Jardiance | European Medicines Agency (EMA), accessed May 27, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance
10. Empagliflozin CAS#: 864070-44-0 - ChemicalBook, accessed May 27, 2025, https://m.chemicalbook.com/ProductChemicalPropertiesCB52627802_EN.htm
11. Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes - PMC, accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4665046/
12. Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near - Frontiers, accessed May 27, 2025, https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2025.1521425/full
13. Cardiovascular Benefit of Empagliflozin Across the Spectrum of ..., accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7382052/
14. Empagliflozin Outcome Trial in Patients With Chronic Heart Failure ..., accessed May 27, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2020/08/28/16/12/EMPEROR-Reduced
15. Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction - Eli Lilly Investors, accessed May 27, 2025, https://investor.lilly.com/news-releases/news-release-details/breakthrough-results-jardiancer-empagliflozin-confirm-emperor
16. Effect of Empagliflozin on Worsening Heart Failure Events in ..., accessed May 27, 2025, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056824
17. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction | Circulation, accessed May 27, 2025, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.059755
18. Trial reports first successful results for heart failure with preserved ..., accessed May 27, 2025, https://www.escardio.org/The-ESC/Press-Office/Press-releases/Trial-reports-first-successful-results-for-heart-failure-with-preserved-ejection-fraction
19. CKD Efficacy | Jardiance® (empagliflozin) tablets, accessed May 27, 2025, https://pro.boehringer-ingelheim.com/us/products/jardiance/ckd/efficacy
20. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors - PMC, accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10387399/
21. FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes, accessed May 27, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-new-class-medicines-treat-pediatric-type-2-diabetes
22. APExBIO - Empagliflozin (BI 10773)|SGLT-2 inhibitor for oral treatment of type 2 diabetes, accessed May 27, 2025, https://www.apexbt.com/empagliflozin-bi-10773.html
23. Empagliflozin | C23H27ClO7 - ChemSpider, accessed May 27, 2025, https://www.chemspider.com/Chemical-Structure.10123957.html
24. AusPAR Attachment 1: Product Information for Empagliflozin ..., accessed May 27, 2025, https://www.tga.gov.au/sites/default/files/auspar-empagliflozin-171026-pi.pdf
25. Empagliflozin, 10 g, CAS No. 864070-44-0 | Research Chemicals | Biochemicals, accessed May 27, 2025, https://www.carlroth.com/com/en/research-chemicals/empagliflozin/p/2lcl.4
26. 864070-44-0 Empagliflozin AKSci X5927, accessed May 27, 2025, https://aksci.com/item_detail.php?cat=X5927
27. SGLT2 Inhibitors in Kidney Diseases—A Narrative Review - MDPI, accessed May 27, 2025, https://www.mdpi.com/1422-0067/25/9/4959
28. Jardiance, INN-Empagliflozin - European Medicines Agency, accessed May 27, 2025, https://www.ema.europa.eu/en/documents/product-information/jardiance-epar-product-information_en.pdf
29. Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a ..., accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3927118/
30. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co ..., accessed May 27, 2025, https://www.jacc.org/doi/10.1016/j.jacbts.2020.02.004
31. The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and ..., accessed May 27, 2025, https://www.mdpi.com/2227-9059/13/3/608
32. SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond ..., accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11146657/
33. Role and mechanisms of SGLT-2 inhibitors in the ... - Frontiers, accessed May 27, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1213473/full
34. JARDIANCE (empagliflozin) tablets, for oral use - accessdata.fda.gov, accessed May 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdf
35. aps.journals.ekb.eg, accessed May 27, 2025, https://aps.journals.ekb.eg/article_397102_23600d021d6542dc9fac0149dcd07687.pdf
36. Biotransformation and mass balance of the SGLT2 inhibitor ..., accessed May 27, 2025, https://www.researchgate.net/publication/270291563_Biotransformation_and_mass_balance_of_the_SGLT2_inhibitor_empagliflozin_in_healthy_volunteers
37. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers | Request PDF - ResearchGate, accessed May 27, 2025, https://www.researchgate.net/publication/258038543_Effect_of_food_on_the_pharmacokinetics_of_empagliflozin_a_sodium_glucose_cotransporter_2_SGLT2_inhibitor_and_assessment_of_dose_proportionality_in_healthy_volunteers
38. www.ema.europa.eu, accessed May 27, 2025, https://www.ema.europa.eu/en/documents/assessment-report/jardiance-epar-public-assessment-report_en.pdf
39. (PDF) Pharmacokinetics, Biotransformation, Distribution and Excretion of Empagliflozin, a Sodium-Glucose Co-Transporter (SGLT 2) Inhibitor, in Mice, Rats, and Dogs - ResearchGate, accessed May 27, 2025, https://www.researchgate.net/publication/281700288_Pharmacokinetics_Biotransformation_Distribution_and_Excretion_of_Empagliflozin_a_Sodium-Glucose_Co-Transporter_SGLT_2_Inhibitor_in_Mice_Rats_and_Dogs
40. Treatment Response to SGLT2 Inhibitors: From Clinical ..., accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8466905/
41. Jardiance (empagliflozin) dosing, indications, interactions, adverse ..., accessed May 27, 2025, https://reference.medscape.com/drug/jardiance-empagliflozin-999907
42. Phase 3 Trial Finds Oral Empagliflozin Provided Safe Glycemic Control in Children with Type 2 Diabetes, accessed May 27, 2025, https://joslin.org/news-stories/all-news-stories/news/2023/02/phase-3-trial-finds-oral-empagliflozin-provided-safe-glycemic-control-children
43. Dinamo 3 | PDF | Health Care | Clinical Medicine - Scribd, accessed May 27, 2025, https://www.scribd.com/document/645664079/dinamo-3
44. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial, accessed May 27, 2025, https://diabetesjournals.org/care/article/40/2/201/37049/Empagliflozin-as-Add-on-Therapy-in-Patients-With
45. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 ..., accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5543566/
46. Empagliflozin Cardiovascular Outcome Event Trial in Type 2 ..., accessed May 27, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2015/09/17/10/11/EMPA-REG-OUTCOME
47. pmc.ncbi.nlm.nih.gov, accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5510032/#:~:text=Empagliflozin%20was%20shown%20to%20be,infarction%2C%20that%20patients%20had%20survived.
48. Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial - PMC, accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5510032/
49. The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support - PMC, accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7868098/
50. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial - PubMed, accessed May 27, 2025, https://pubmed.ncbi.nlm.nih.gov/33175585/
51. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age | JACC, accessed May 27, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2022.04.040
52. SGLT2 inhibitors in patients with HFpEF: how old is too old? - PMC, accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9354734/
53. Plain language summary of a study looking at the effect of ..., accessed May 27, 2025, https://academic.oup.com/ckj/article/17/5/sfae057/7624217
54. Landmark EMPA-KIDNEY trial showed significant benefit of ..., accessed May 27, 2025, https://investor.lilly.com/news-releases/news-release-details/landmark-empa-kidney-trial-showed-significant-benefit-jardiancer
55. Full data announced in phase III EMPA-KIDNEY trial | Boehringer Ingelheim, accessed May 27, 2025, https://www.boehringer-ingelheim.com/us/human-health/chronic-kidney-disease/full-data-announced-phase-iii-empa-kidney-trial
56. JARDIANCE® (empagliflozin - accessdata.fda.gov, accessed May 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204629s033lbl.pdf
57. Empagliflozin - StatPearls - NCBI Bookshelf, accessed May 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK532925/
58. Does Empagliflozin cause Urinary Tract Infection? Read What Users Report - Drugs.com, accessed May 27, 2025, https://www.drugs.com/comments/empagliflozin/sfx-urinary-tract-infection.html
59. Jardiance (empagliflozin): Side effects, dosage, uses, and more - Medical News Today, accessed May 27, 2025, https://www.medicalnewstoday.com/articles/326007
60. Reminder: Flozins and the risks of diabetic ketoacidosis and Fournier's, accessed May 27, 2025, https://www.medsafe.govt.nz/profs/PUArticles/December2022/Flozins-risks-diabetic-ketoacidosis-Fourniers-gangrene.html
61. www.journalrip.com, accessed May 27, 2025, https://www.journalrip.com/PDF/jrip-13-e32276.pdf
62. SmPC Jardiance 10 and 25mg CCDS 0278-24 .docx - NAFDAC Greenbook Admin, accessed May 27, 2025, https://admin.greenbook.nafdac.gov.ng/uploadImage/smpc_files/2025/03/28/202503282e419f1f-6e60-5340-bdc8-5ef5f984d63c.pdf
63. Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes, accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4450666/
64. The incidence of diabetic ketoacidosis associated with empagliflozin use in Aotearoa New Zealand: a preliminary review, accessed May 27, 2025, https://nzmj.org.nz/media/pages/journal/vol-135-no-1555/the-incidence-of-diabetic-ketoacidosis-associated-with-empagliflozin-use-in-aotearoa-new-zealand-a-preliminary-review/adf3ab6b2e-1696471769/the-incidence-of-diabetic-ketoacidosis-associated-with-empagliflozin-use-in-aotearoa-new-zealand-a-preliminary-review.pdf
65. Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports - PMC, accessed May 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9793230/
66. Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis) - Canada.ca, accessed May 27, 2025, https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin.html
67. Empagliflozin Use and Fournier's Gangrene: Case Report and Systematic Literature Review, accessed May 27, 2025, https://www.mdpi.com/2673-4095/2/2/18
68. Full article: Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study, accessed May 27, 2025, https://www.tandfonline.com/doi/full/10.1080/14740338.2022.2054987
69. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study - PubMed, accessed May 27, 2025, https://pubmed.ncbi.nlm.nih.gov/31769309/
70. SYNJARDY (empagliflozin and metformin hydrochloride) tablets - accessdata.fda.gov, accessed May 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206111lbl.pdf
71. Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors - StatPearls - NCBI Bookshelf, accessed May 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK576405/
72. Drug Interaction Report: empagliflozin, primidone - Drugs.com, accessed May 27, 2025, https://www.drugs.com/interactions-check.php?drug_list=3548-0,1940-0&professional=1
73. SYNJARDY XR (empagliflozin and metformin hydrochloride extended release) tablets - accessdata.fda.gov, accessed May 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208658s001lbl.pdf
74. New TGA indication for empagliflozin - NPS MedicineWise, accessed May 27, 2025, https://www.nps.org.au/news/new-tga-indication-for-empagliflozin